Clinical trial
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer…
NCT00001703 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00001703 |
|---|---|
| Title | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma |
| Official title | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Biological |
| Interventions | incomplete Freund's adjuvant, von Hippel-Lindau peptide vaccine |
| Enrollment | 6 |
| Start date | Aug 1, 1998 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Nov 4, 1999 |
| Last update posted | Jul 25, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: